300942.SZ
易瑞生物
SZSE · Healthcare · C 制造业 · CN
CNY 6.98
+3.87%Year over year
Reported trailing growth
- Revenue
- +14.5%
- EBITDA
- —
- EBIT
- —
- EPS
- -63.0%
- Free cash flow
- +93.9%
- Operating cash flow
- +138.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -27.4%
- EBITDA
- -31.9%
- EBIT
- -61.5%
- Net income
- -45.1%
- EPS
- -47.7%
- Free cash flow
- +115.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026